Both gumokimab and manfidokimab met their primary endpoints, as Akeso oversees NDAs with the NMPA for both drugs.

WCG has introduced Total Training, a clinical trial solution designed to reduce protocol deviations and enhance site ...

Coya Therapeutics has announced the acceptance by the US FDA of IND application for COYA 302, paving the way for a Phase II ...